This week at the SCC

Nov. 8 – Federal – AstraZeneca Canada, et al. v. Apotex, et al.
Civil: The applicants owned a patent for esomeprazole, a proton pump inhibitor used in the reduction of gastric acid, reflux esophagitis and related conditions. It was sold under the name Nexium, and was a very successful product for AstraZeneca. The respondents applied to the Minister of Health to obtain a Notice of Compliance which would allow it to sell its generic version of the drug. In response, AstraZeneca brought a prohibition application under the Patented Medicines Regulations to prevent Apotex from entering the market until after the expiry of its …
Go to Source